Works matching IS 03407004 AND DT 2023 AND VI 72 AND IP 9

Results: 20
    1

    The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity.

    Published in:
    Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3097, doi. 10.1007/s00262-023-03483-7
    By:
    • Girone, Carlo;
    • Calati, Federica;
    • Lo Cigno, Irene;
    • Salvi, Valentina;
    • Tassinari, Valentina;
    • Schioppa, Tiziana;
    • Borgogna, Cinzia;
    • Lospinoso Severini, Ludovica;
    • Hiscott, John;
    • Cerboni, Cristina;
    • Soriani, Alessandra;
    • Bosisio, Daniela;
    • Gariglio, Marisa
    Publication type:
    Article
    2
    3
    4
    5

    Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.

    Published in:
    Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3029, doi. 10.1007/s00262-023-03474-8
    By:
    • Battin, Claire;
    • De Sousa Linhares, Annika;
    • Leitner, Judith;
    • Grossmann, Anna;
    • Lupinek, Daniela;
    • Izadi, Shiva;
    • Castilho, Alexandra;
    • Waidhofer-Söllner, Petra;
    • Grabmeier-Pfistershammer, Katharina;
    • Stritzker, Jochen;
    • Steinberger, Peter
    Publication type:
    Article
    6
    7
    8
    9

    Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.

    Published in:
    Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 3013, doi. 10.1007/s00262-023-03470-y
    By:
    • Egelston, Colt A.;
    • Guo, Weihua;
    • Yost, Susan E.;
    • Ge, Xuan;
    • Lee, Jin Sun;
    • Frankel, Paul H.;
    • Cui, Yujie;
    • Ruel, Christopher;
    • Schmolze, Daniel;
    • Murga, Mireya;
    • Tang, Aileen;
    • Martinez, Norma;
    • Karimi, Misagh;
    • Somlo, George;
    • Lee, Peter P.;
    • Waisman, James R.;
    • Yuan, Yuan
    Publication type:
    Article
    10

    Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.

    Published in:
    Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2961, doi. 10.1007/s00262-023-03469-5
    By:
    • Santoni, Matteo;
    • Myint, Zin W.;
    • Büttner, Thomas;
    • Takeshita, Hideki;
    • Okada, Yohei;
    • Lam, Elaine T.;
    • Gilbert, Danielle;
    • Küronya, Zsófia;
    • Tural, Deniz;
    • Pichler, Renate;
    • Grande, Enrique;
    • Crabb, Simon J.;
    • Kemp, Robert;
    • Massari, Francesco;
    • Scagliarini, Sarah;
    • Iacovelli, Roberto;
    • Vau, Nuno;
    • Basso, Umberto;
    • Maruzzo, Marco;
    • Molina-Cerrillo, Javier
    Publication type:
    Article
    11
    12

    Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).

    Published in:
    Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2991, doi. 10.1007/s00262-023-03467-7
    By:
    • Shi, Yuankai;
    • Cui, Jie;
    • Zhou, Hui;
    • Zhang, Xiaohong;
    • Zou, Liqun;
    • Cao, Junning;
    • Gao, Yuhuan;
    • Jin, Chuan;
    • Li, Xiaoling;
    • Liu, Hui;
    • Peng, Zhigang;
    • Xie, Liping;
    • Zhang, Huilai;
    • Zhang, Weihua;
    • Zhang, Hongyu;
    • Zhong, Liye;
    • Zhou, Fang;
    • Guo, Genny;
    • He, Wenduo
    Publication type:
    Article
    13

    Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.

    Published in:
    Cancer Immunology, Immunotherapy, 2023, v. 72, n. 9, p. 2949, doi. 10.1007/s00262-023-03466-8
    By:
    • Zhu, Chengpei;
    • Li, Hu;
    • Yang, Xiaobo;
    • Wang, Shanshan;
    • Wang, Yunchao;
    • Zhang, Nan;
    • Wang, Yanyu;
    • Xue, Jingnan;
    • Zhang, Longhao;
    • Ning, Cong;
    • Yang, Xu;
    • Xun, Ziyu;
    • Chao, Jiashuo;
    • Long, Junyu;
    • Sang, Xinting;
    • Zhu, Zhenyu;
    • Zhao, Haitao
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20